Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Stereotactic Body Radiation Therapy for the Treatment of Metastatic Renal Cell Carcinoma in Patients with Oligoprogression on Immune Checkpoint Inhibitors

Trial Status: active

This phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) in patients who have developed disease progression at a limited number of sites (up to 5) (oligoprogression) after treatment with immune checkpoint inhibitor drugs. Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Adding SBRT and continuing standard immune checkpoint inhibitor treatment may prolong survival without progression of metastatic renal cell cancer compared to standard of care which will include second line systemic therapy.